School of Medicine
Showing 81-90 of 218 Results
-
Erin Watson, PsyD, ABPP
Clinical Associate Professor, Medicine - Gastroenterology & Hepatology
BioDr. Erin Watson is a board-certified clinical health psychologist and Clinical Associate Professor in the Division of Gastroenterology & Hepatology at Stanford University School of Medicine. She is a member of Stanford Health Care’s GI Behavioral Medicine program, where she specializes in the intersection of psychological health, behavioral science, and gastrointestinal and liver disease.
Dr. Watson’s clinical work focuses on helping patients navigate the emotional, behavioral, and lifestyle factors that influence medical illness. Her areas of expertise include health anxiety, stress and symptom management, health-behavior change, adjustment to chronic conditions, and the emerging specialty of psycho-hepatology. She uses practical, evidence-based approaches—including cognitive behavioral therapy, acceptance and commitment therapy, mindfulness-based interventions, and motivational interviewing—with lifestyle-medicine strategies to support long-term health and resilience. Her goal is to help patients feel more informed, supported, and empowered throughout their care.
In addition to her clinical work, Dr. Watson is engaged in research to advance behavioral treatments for chronic pain and develop new psychological interventions for individuals living with chronic liver disease. She is a co-investigator on a National Institutes of Health–funded study examining effective treatment options for veterans with chronic pain and addiction. Her scholarly work has been published in peer-reviewed journals and presented at regional and national conferences, including annual meetings of the American Psychological Association.
Dr. Watson is a Fellow of the American Academy of Clinical Health Psychology and a member of the American Psychological Association, the Society for Health Psychology (Division 38), the Society of Behavioral Medicine, the American Association for the Study of Liver Diseases, and the Rome Foundation. -
Kathleen Watson
Instructor, Psychiatry and Behavioral Sciences
BioKathleen Watson, Ph.D., currently serves as an instructor at Stanford University School of Medicine, specializing in Epidemiology and Clinical Research. She co-founded Microclinic International in 2007, where she served as Chief Operating Officer until 2012, focusing on socially-based health interventions for underserved communities.
Dr. Watson's research encompasses various aspects of mental health and metabolism. She investigates the connection between insulin resistance and depression, using computational psychiatry to uncover insights into the interplay of metabolic factors in mental well-being. Additionally, her exploration of cognitive aging examines how metabolic alterations might impact cognitive decline and related disorders. Furthermore, her research in proteomics aims to identify potential biomarkers for severe major depressive disorder. Dr. Watson has recently become a part of the Stanford Autism Center for Excellence Data Core, where she works under the guidance of Dr. Booil Jo. -
Robert Waymouth
Robert Eckles Swain Professor of Chemistry and Professor, by courtesy, of Chemical Engineering
BioRobert Eckles Swain Professor in Chemistry Robert Waymouth investigates new catalytic strategies to create useful new molecules, including bioactive polymers, synthetic fuels, and sustainable plastics. In one such breakthrough, Professor Waymouth and Professor Wender developed a new class of gene delivery agents.
Born in 1960 in Warner Robins, Georgia, Robert Waymouth studied chemistry and mathematics at Washington and Lee University in Lexington, Virginia (B.S. and B.A., respectively, both summa cum laude, 1982). He developed an interest in synthetic and mechanistic organometallic chemistry during his doctoral studies in chemistry at the California Institute of Technology under Professor R.H. Grubbs (Ph.D., 1987). His postdoctoral research with Professor Piero Pino at the Institut fur Polymere, ETH Zurich, Switzerland, focused on catalytic hydrogenation with chiral metallocene catalysts. He joined the Stanford University faculty as assistant professor in 1988, becoming full professor in 1997 and in 2000 the Robert Eckles Swain Professor of Chemistry.
Today, the Waymouth Group applies mechanistic principles to develop new concepts in catalysis, with particular focus on the development of organometallic and organic catalysts for the synthesis of complex macromolecular architectures. In organometallic catalysis, the group devised a highly selective alcohol oxidation catalyst that selectively oxidizes unprotected polyols and carbohydrates to alpha-hyroxyketones. In collaboration with Dr. James Hedrick of IBM, we have developed a platform of highly active organic catalysts and continuous flow reactors that provide access to polymer architectures that are difficult to access by conventional approaches.
The Waymouth group has devised selective organocatalytic strategies for the synthesis of functional degradable polymers and oligomers that function as "molecular transporters" to deliver genes, drugs and probes into cells and live animals. These advances led to the joint discovery with the Wender group of a general, safe, and remarkably effective concept for RNA delivery based on a new class of synthetic cationic materials, Charge-Altering Releasable Transporters (CARTs). This technology has been shown to be effective for mRNA based cancer vaccines. -
Kenneth Weber, DC, PhD
Assistant Professor (Research) of Anesthesiology, Perioperative and Pain Medicine (Adult Pain) and, by courtesy, of Neurosurgery (Adult Neurosurgery) and of Radiology (Neuroimaging and Neurointervention)
BioDr. Weber directs the Neuromuscular Insight Lab. Dr. Weber's research seeks to develop quantitative markers of sensory and motor function, including pain, using machine-learning and advanced brain, spinal cord, and musculoskeletal magnetic resonance imaging. Dr. Weber aims to use these techniques to better understand the neuropathology of neurological and musculoskeletal conditions and discover more effective treatments and preventative strategies.
-
Mike Tzuhen Wei
Clinical Assistant Professor, Medicine - Gastroenterology & Hepatology
BioDr. Wei was born and raised in Taipei, Taiwan. He went to Stanford for his undergraduate studies in Biology and earned his medical degree at Weill Cornell Medical College. Unable to stay far from the Bay Area, he returned to Stanford where he completed his residency in internal medicine and subsequently his fellowship in gastroenterology. Dr. Wei has specific interests in colorectal cancer and Barrett’s esophagus surveillance as well as reflux diagnosis and management. He has an interest in endoscopic resection of large polyps and had received training under Dr. Shai Friedland, a world expert in this field. Dr. Wei work focuses on evaluating new tools, technologies and techniques in gastrointestinal cancer surveillance and management. He has been involved in running several trials in endoscopic management of polyps and evaluating artificial intelligence applications in gastroenterology. His work has been published in American Journal of Gastroenterology, Gastrointestinal Endoscopy, Clinical Endoscopy, VideoGIE, and Digestive Diseases and Sciences. He was formerly an Associate Editor for the ACG Case Report Journal (2020-2022) and was on the Board of the Northern California Society of Clinical Gastroenterology. When not in clinic or in endoscopy, Dr. Wei enjoys spending time with his family. He and his family enjoy traveling and exploring new restaurants.
-
Katja Gabriele Weinacht, MD, PhD
Assistant Professor of Pediatrics (Stem Cell Transplantation and Regenerative Medicine)
Current Research and Scholarly InterestsPediatric Hematopoietic Stem Cell Transplantation
DiGeorge Syndrome
Genetic Immune Diseases
Immune Dysregulation -
Ann Weinacker
Professor of Medicine (Pulmonary and Critical Care)
Current Research and Scholarly InterestsDr. Weinacker's research interests center around ICU outcomes. Her specific interests include primary graft dysfunction in lung transplant recipients.
